Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-15
2011-03-15
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S256000
Reexamination Certificate
active
07906533
ABSTRACT:
The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
REFERENCES:
patent: 3226394 (1965-12-01), Schippet et al.
patent: 4568687 (1986-02-01), Wright et al.
patent: 5716993 (1998-02-01), Ozaki et al.
patent: 6448277 (2002-09-01), Altmann et al.
patent: 6548548 (2003-04-01), Campbell et al.
patent: 6818661 (2004-11-01), Seidelmann et al.
patent: 6878720 (2005-04-01), Altmann et al.
patent: 7002022 (2006-02-01), Altmann et al.
patent: 7122547 (2006-10-01), Huth et al.
patent: 7148357 (2006-12-01), Huth et al.
patent: 7202260 (2007-04-01), Huth et al.
patent: 7307088 (2007-12-01), Huang et al.
patent: 7429592 (2008-09-01), Ernst et al.
patent: 2002/0019414 (2002-02-01), Altmann et al.
patent: 2002/0147198 (2002-10-01), Chen et al.
patent: 2003/0134836 (2003-07-01), Elbaum et al.
patent: 2003/0176469 (2003-09-01), Seidelmann et al.
patent: 2003/0225106 (2003-12-01), Askew et al.
patent: 2004/0029880 (2004-02-01), Krueger et al.
patent: 2004/0039019 (2004-02-01), Huth et al.
patent: 2004/0102441 (2004-05-01), Krueger et al.
patent: 2004/0254185 (2004-12-01), Ernst et al.
patent: 2004/0266770 (2004-12-01), Ernst et al.
patent: 2005/0032816 (2005-02-01), Ernst
patent: 2005/0054654 (2005-03-01), Huth et al.
patent: 2005/0261343 (2005-11-01), Krueger et al.
patent: 2006/0116380 (2006-06-01), Bohlmann et al.
patent: 2006/0160861 (2006-07-01), Bohlmann et al.
patent: 2006/0264425 (2006-11-01), Bohlmann et al.
patent: 2007/0015794 (2007-01-01), Huth et al.
patent: 2007/0135489 (2007-06-01), Huth et al.
patent: 2652144 (1978-05-01), None
patent: 3406416 (1984-08-01), None
patent: 19910396 (2000-09-01), None
patent: 10023486 (2002-03-01), None
patent: 10228090 (2004-01-01), None
patent: 0564356 (1993-10-01), None
patent: 0650961 (1995-05-01), None
patent: 06/86625 (1995-12-01), None
patent: 50157383 (1975-12-01), None
patent: WO 9426260 (1994-11-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 00/27819 (2000-05-01), None
patent: WO 00/27820 (2000-05-01), None
patent: WO 00/39118 (2000-07-01), None
patent: WO 01/55114 (2001-08-01), None
patent: WO 01/85715 (2001-11-01), None
patent: WO 0185691 (2001-11-01), None
patent: WO 02055501 (2002-07-01), None
patent: WO 02/090352 (2002-11-01), None
patent: WO 02066470 (2002-11-01), None
patent: WO 02090352 (2002-11-01), None
patent: WO 03/040102 (2003-05-01), None
patent: WO 03048158 (2003-06-01), None
patent: WO 2004/013102 (2004-02-01), None
Augustin et al.: “Antiangiogenic Tumour Therapy: Will It Work?” Elsevier Trends Journal, vol. 19, No. 6, Jun. 1, 1998, pp. 216-222, XP004145666.
Strandtmann et al., J. Med. Chem. vol. 10, No. 6, 1967, pp. 1063-1065.
Sofina et al.: “Experimental Evaluation of Anti-Tumor Drugs in the USA and USSR and Clincal Correltaions,” NCI Monograph 55, NIH Publication No. 80-1933 (1980).
Wermuth et al.: “The Practice of Medicinal Chemistry” Practice of Medicninal Chemistry XX, XX, 1996 pp. 203-237, XP002190259.
Montginoul et al.: “Analgesic, Anticonvulsant and Anti-Inflammatory Activities of 1H, 3H-Quinazoline-2,4-Diones” Chemical Abstracts Service, Coloumbus, Ohio, US; Retreived From STN Database Accession No. 110:165551H; XP002135868; Ann. Pharm. FR (1989) vol. 46, No. 4, pp. 223-232.
Noda et al.: “Quinazoline Compounds” Chemical Abstracts, Jul. 19, 1976, vol. 85, No. 3, XP002135867.
Hardtmann et al.: “Chemistry of 2H-3,1-Benzoxazine-2,4 (1H)-Dione (Isatoic Anhydrides). I. Sythesis of N-Substituted2H-3,1-Benzoxazine-2,4(1H)-Dione” Journal of Heterocyclic Chemistry, 1975,vol. 12, No. 3, pp. 565-572, Heterocorporation, XP002135866.
Pastor et al.: “Synthesis of New 1H,3H-Quinazoline-2,4-Diones”, Bulletin de la Societe Chimique de France, vol. 5-6, No. 2, 1975, pp. 1331-1338, XP002135865.
Manley et al.: “Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors”, J. Med. Chem., 2002, vol. 45, pp. 5687-5693.
Golub et al. “Science” 1999, vol. 286, pp. 521-537.
Lala et al.: “Cancer and Metastasis Reviews” 1998, vol. 17, No. 1, pp. 91-106.
Verweij et al.: “Multi-Tatget Tyrosine Kinase Inhibition: and the Winner is . . . ”, Journal of Clinical Oncology, vol. 25, No. 17, Jun. 10, 2007.
Hanrahan et al.: “Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD217 in Lung Cancer”, Cliical Cancer Search 2007; vol. 13 (15 Suppl) Aug. 1, 2007.
U.S. Appl. No. 10/631,018.
U.S. Appl. No. 11/525,091.
English Abstracts of Hardtmann et al.: “Chemistry of 2H-3,1-Benzoxazine-2,4 (1H)-Dione (Isatoic Anhydrides). I. Sythesis of N-Substituted2H-3,1-Benzoxazine-2,4(1H)-Dione” Journal of Heterocyclic Chemistry, 1975,vol. 12, No. 3, pp. 565-572, Heterocorporation, XP002135866.
English Abstracts of Pastor et al.: “Synthesis of New 1H,3H-Quinazoline-2,4-Diones”, Bulletin de la Societe Chimique de France, vol. 5-6, No. 2, 1975, pp. 1331-1338, XP002135865.
Non Final Rejection Dated Dec. 5, 2008—U.S. Appl. No. 11/262,953, filed Nov. 1, 2005 (Publication No. 2006/0160861 A1).
Final Rejection Dated Dec. 17, 2008—U.S. Appl. No. 11/525,091, filed Sep. 22, 2006 (Publication No. 2007/0015794 A1).
Non Final Rejection Dated Mar. 17, 2008—U.S. Appl. No. 11/525,091, filed Sep. 22, 2006 (Publication No. 2007/0015794 A1).
Non Final Rejection Dated Oct. 8, 2008—U.S. Appl. No. 11/265,516, filed Nov. 3, 2005 (Publication No. 2006/0264426 A1).
Non Final Rejection Dated Dec. 6, 2005—U.S. Appl. No. 10/631,018, filed Jul. 31, 2003 (Publication No. 2004/0147535 A1).
Non Final Rejection Dated Nov. 24, 2004—U.S. Appl. No. 10/275,479, filed Jun. 23, 2003 (Publication No. 2004/00298880 A1).
Final Rejection Dated May 3, 2005—U.S. Appl. No. 10/275,480, filed Jun. 24, 2003 (Publication No. 2004/0102441 A1).
Non Final Rejection Dated Nov. 19, 2004—U.S. Appl. No. 10/275,480, filed Jun. 24, 2003 (Publication No. 2004/0102441 A1).
Non Final Rejection Dated Mar. 3, 2004—U.S. Appl. No. 10/275,480, filed Jun. 24, 2003 (Publication No. 2004/0102441 A1).
Non Final Rejection Dated Apr. 2, 2007—U.S. Appl. No. 10/476,761, filed Aug. 25, 2004 (Publication No. 2004/0266770 A1).
Non Final Rejection Dated Feb. 21, 2002—U.S. Appl. No. 09/831,506, filed Sep. 14, 2001.
Non Final Rejection Dated Jun. 12, 2002—U.S. Appl. No. 09/831,506, filed Sep. 14, 2001.
Final Rejection Dated Dec. 30, 2002—U.S. Appl. No. 09/831,506, filed Sep. 14, 2001.
Non Final Rejection Dated Mar. 25, 2004—U.S. Appl. No. 09/831,506, filed Sep. 14, 2001.
Final Rejection Dated Dec. 9, 2008—U.S. Appl. No. 10/477,119, filed Jun. 23, 2004 (Publication No. 2004/0254185 A1).
Non Final Rejection Dated Mar. 11, 2008—U.S. Appl. No. 10/477,119, filed Jun. 23, 2004 (Publication No. 2004/0254185 A1).
Non Final Rejction Dated Nov. 14, 2008—U.S. Appl. No. 11/265,517, filed Nov. 3, 2005 (Publication No. 2006/0116380 A1).
Carmeliet et al.: “Angiogenesis in Cancer and Other Diseases”; Macmilliam Magazines Ltd., 2000, vol. 407, p. 249-257.
English Abstract of JP 50157383 A.
English Abstract of DE 2652144 A.
English Abstract of EP 0564356 A1: 4-Phenylaminomethylimidazole Derivatives, Process for Their Preparation, Angiotensin II Receptor Antagonist and Their Application in Therapy [German] [French], Dodey, Pierre et al. Jan. 4, 1992.
Bohlmann Rolf
Haberey Martin
Hess-Stumpp Holger
Huth Andreas
Ince Stuart
Bayer Schering Pharma AG
Millen White Zelano & Branigan P.C.
Morris Patricia L
LandOfFree
Nicotinamide pyridinureas as vascular endothelial growth... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotinamide pyridinureas as vascular endothelial growth..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotinamide pyridinureas as vascular endothelial growth... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2723885